Alimera Sciences Inc. is a biopharmaceutical company that engaged in the research development and commercialization of ophthalmic pharmaceuticals.


Updates from The Motley Fool

Latest updates on Alimera Sciences from Fool.com.
2 Stocks Stopping the Presses

You saw the headlines. You know your stock price made a big move. But what does that portend fo...

Alimera Annihilates Its Doubters

It's a good thing the shorts largely stayed away from Alimera ( Nasdaq: ALIM     ) , or these...

5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this ...

These 2 Biotechs Got Crushed

On a day when the Dow Jones Industrial Average ( INDEX: ^DJI     ) surged 260 points as the E...

Hidden Stocks for High Returns

Like the song says, investors are looking for stocks to love in all the wrong places . They'll ...

Why Did My Stock Just Die?

Your stock just took a nosedive -- but don't panic. First, let's see whether it had good reason t...

Hidden Stocks for High Returns

Like the song says, investors are looking for stocks to love in all the wrong places . They'll ...



Stock Performance

View Interactive ALIM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alimera Sciences.
Current Price: $1.16
Prev Close: $1.15
Open: $1.14
Bid: $1.18
Ask: $1.20
Day's Range: $1.12 - $1.16
52wk Range: $1.02 - $5.15
Volume: 231,252
Avg Vol 278,395
Market Cap: $52M
P/E (ttm): -1.44
EPS (ttm): ($0.80)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alimera Sciences.
CAPS Rating 1 out of 5
 
66 Outperform
17 Underperform
CAPS All Stars
 
6 Outperform
8 Underperform

How do you think Alimera Sciences will perform against the market?



You pick for Alimera Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

C. Daniel Myers, CEO

100% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alimera Sciences.

Alimera Sciences Inc. is a biopharmaceutical company that engaged in the research development and commercialization of ophthalmic pharmaceuticals.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers